公开(公告)号：US20180325640A1

公开(公告)日：2018-11-15

申请号：US15515638

申请日：2015-09-23

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： BART GOTTENBOS ,  AMIR HUSSEIN RMAILE ,  MARINUS KAREL JOHANNES DE JAGER ,  CARL GLASSE

IPC: A61C19/06 ,  A61C15/04 ,  A61C17/02 ,  A61C17/36

CPC classification number: A61C19/063 ,  A61C15/041 ,  A61C15/047 ,  A61C17/02 ,  A61C17/36

Abstract: Disclosed is a new method, and a system, for the delivery of particles comprising at least one oral care agent to the oral cavity, so as to particularly enable delivery into the interproximal spaces. The method involves providing a liquid comprising the particles and introducing the liquid into the oral cavity in the form of a fluid jet, said jet having a velocity of from 0.5 m/s to 5 m/s. The fluid jet can be generated by an appropriately adapted oral irrigator, but other devices can be used as well. The invention is particularly suitable for the delivery of adhesive gel particles comprising one or more oral care agents, preferably particles for the controlled and/or slow release of such agents.

公开(公告)号：US20210063412A1

公开(公告)日：2021-03-04

申请号：US16962249

申请日：2019-01-09

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： GERBEN KOOIJMAN ,  AMIR HUSSEIN RMAILE ,  CARL GLASSE ,  MARINUS KAREL JOHANNES DE JAGER ,  IAIN LESLIE CAMPBELL CHAPPLE ,  MELISSA MACKAY GRANT ,  MICHAEL ALEX VAN HARTSKAMP ,  PHILIP PRESHAW ,  JOHN J. TAYLOR

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the Free Light Chain κ protein and/or the Free Light Chain λ. Based on the concentration(s) as measured, a value is determined reflecting the concentration or joint concentrations for said protein or proteins. This value is compared with a threshold value reflecting in the same manner the concentration or joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a concentration or joint concentration below the concentration or joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a concentration or joint concentration at or above the concentration or joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.

公开(公告)号：US20210148935A1

公开(公告)日：2021-05-20

申请号：US17046882

申请日：2019-04-10

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： GERBEN KOOIJMAN ,  AMIR HUSSEIN RMAILE ,  CARL GLASSE ,  MARINUS KAREL JOHANNES DE JAGER ,  IAIN LESLIE CAMPBELL CHAPPLE ,  MELISSA MACKAY GRANT ,  PHILIP PRESHAW ,  JOHN TAYLOR ,  MICHAEL ALEX VAN HARTSKAMP

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

公开(公告)号：US20210025903A1

公开(公告)日：2021-01-28

申请号：US17045605

申请日：2019-04-10

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： GERBEN KOOIJMAN ,  AMIR HUSSEIN RMAILE ,  CARL GLASSE ,  MARINUS KAREL JOHANNES DE JAGER ,  IAIN LESLIE CAMPBELL CHAPPLE ,  MELISSA MACKAY GRANT ,  PHILIP PRESHAW ,  JOHN TAYLOR ,  MICHAEL ALEX VAN HARTSKAMP

IPC: G01N33/68

Abstract: Disclosed is an in vitro method for assessing whether a human patient has gingivitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from gingivitis, the concentrations are measured of the certain protein combinations. One such combination is Alpha-1-acid glycoprotein (A1AGP) and at least one of Matrix metal-loproteinase-8 (MMP8), Matrix metalloproteinase-9 (M MP9), Hepatocyte growth factor (HGF), Hemoglobin subunit beta (Hb-beta), and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with gingivitis. The comparison allows assessing whether the testing value is indicative of the presence of gingivitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of gingivitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for gingivitis in said patient.

公开(公告)号：US20190216585A1

公开(公告)日：2019-07-18

申请号：US16305962

申请日：2017-05-30

Applicant: KONINKLIJKE PHILIPS N.V.

Inventor： BART GOTTENBOS ,  CARL GLASSE

IPC: A61C19/06 ,  A61C15/00 ,  A61K9/00 ,  A61K47/36 ,  A61K47/26 ,  A61K47/12 ,  A61K9/06

CPC classification number: A61C19/063 ,  A61C15/00 ,  A61K9/0063 ,  A61K9/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36

Abstract: Disclosed is a method, and a system, for accomplishing the in situ formation of a gel in an interdental space. This is useful for the interdental application of one or more dental care agents, such as antimicrobial agents or other anti-plaque agents. The invention makes use of a two component system comprising a gelable liquid and a liquid gelling agent capable of bringing about gelation of the liquid. The system of the invention is arranged such that first the gelable, typically viscous, liquid can be applied, and then the liquid gelling agent is forced, e.g. jetted, into the applied gelable liquid. The system is designed such as to prevent the gelling agent and the gelable liquid to come into contact with each other before both have been applied. The system is configured to allow the gelable liquid to be applied prior to the gelling agent.